Promore Pharma AB (publ) (PROMO.ST)
Promore Pharma AB (publ) operates in the Biotechnology industry of the Healthcare sector, headquartered in Solna, SE. The stock last traded at $0.11, up 13.17% on the session, giving a market capitalisation of $293.5M. Its beta of 1.51 implies it has historically moved more than the broad market.
Promore Pharma AB (publ) is a Swedish biopharmaceutical firm dedicated to advancing peptide-based drug therapies. The company's development pipeline features PXL01, currently undergoing Phase IIa studies for its potential in preventing post-surgical adhesions and scars, mitigating dermal scarring, and aiding hand tendon repair. Another key asset, LL-37, is engaged in Phase IIb clinical trials to address venous leg ulcers, stimulate the healing of persistent wounds, and treat diabetic foot ulcers. Additionally, Promore Pharma has partnered with Fidia Farmaceutici S.p.A. for the production of hyaluronic acid syringes. Founded in 2002, the company, formerly known as Lipopeptide AB until its rebranding in January 2017, maintains its headquarters in Solna, Sweden.
Promore Pharma AB (publ) is most often compared with the following Healthcare names: